296787-77-4

Basic information

• Product Name: (R)-4-phenyl-2-phenylmethanesulfonylamino-butyric acid
• Synonyms: (R)-4-phenyl-2-phenylmethanesulfonylamino-butyric acid
• CAS NO: 296787-77-4
• Molecular Weight: 333.408
• Mol File: 296787-77-4.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: (R)-4-phenyl-2-phenylmethanesulfonylamino-butyric acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-phenyl-2-phenylmethanesulfonylamino-butyric acid(296787-77-4)
• EPA Substance Registry System: (R)-4-phenyl-2-phenylmethanesulfonylamino-butyric acid(296787-77-4)

Safety Data

• Hazardous Substances Data: 296787-77-4(Hazardous Substances Data)

Upstream product

• 82795-51-5 D-homophenylalanine 
• 1939-99-7 benzenesulfonyl chloride 
• 673-06-3 D-(R)-phenylalanine 
• 123-91-1 1,4-dioxane 

Downstream Products

• 1221593-82-3 (S)-4-[4-(N-acetylhydroxycarbaininiidoyl)-benzylcarbamoyl]-4-((R)-4-phenyl-2-phenylmethanesulfonylamino-butyrylamino)-butyric acid benzyl ester 
• 1221593-82-3 (S)-benzyl 5-(4-((Z)-N'-acetoxycarbamimidoyl)benzylamino)-5-oxo-4-((R)-4-phenyl-2-(phenylmethylsulfonamido)butanamido)pentanoate 

Relevant articles and documents

Pharmaceutical compositions with attenuated release of phenolic opioids

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with th

COMPOSITIONS COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG

The embodiments provide Compound PC-5, [2-((S)-2-malonylamino-6-amino-hexanoyl amino)-ethyl]-ethyl-carbamic acid hydromorphone ester, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug, Compound PC-5, that provides enzymatically-controlled release of hydromorphone, and, optionally, a trypsin inhibitor that interacts with the enzyme that mediates the enzymatically-controlled release of hydromorphone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.